###begin article-title 0
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of Northern Spain
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 377 381 377 381 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 424 428 424 428 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 468 474 468 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
Polymorphisms in DNA repair genes have been associated to repair DNA lesions, and might contribute to the individual susceptibility to develop different types of cancer. Nucleotide excision repair (NER), base excision repair (BER), and double-strand break repair (DSBR) are the main DNA repair pathways. We investigated the relationship between polymorphisms in two NER genes, XPC (poly (AT) insertion/deletion: PAT-/+) and XPD (Asp312Asn and Lys751Gln), the BER gene XRCC1 (Arg399Gln), and the DSBR gene XRCC3 (Thr241Met) and the risk of developing lung cancer.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 70 78 <span type="species:ncbi:9606">patients</span>
A hospital-based case-control study was designed with 516 lung cancer patients and 533 control subjects, matched on ethnicity, age, and gender. Genotypes were determined by PCR-RFLP and the results were analysed using multivariate unconditional logistic regression, adjusting for age, gender and pack-years.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 45 49 45 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 149 160 149 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT+/+ </italic>
###xml 391 395 391 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 414 425 414 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn/Asn </italic>
###xml 429 439 429 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink">751Gln/Gln</italic>
###xml 805 812 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln </italic>
###xml 929 940 929 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln/Gln </italic>
###xml 1054 1060 1054 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 1151 1162 1151 1162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">241Met/Met </italic>
Borderline association was found for XPC and XPD NER genes polymorphisms, while no association was observed for polymorphisms in BER and DSBR genes. XPC PAT+/+ genotype was associated with no statistically significant increased risk among ever smokers (OR = 1.40; 95%CI = 0.94-2.08), squamous cell carcinoma (OR = 1.44; 95%CI = 0.85-2.44), and adenocarcinoma (OR = 1.72; 95%CI = 0.97-3.04). XPD variant genotypes (312Asn/Asn and 751Gln/Gln) presented a not statistically significant risk of developing lung cancer (OR = 1.52; 95%CI = 0.91-2.51; OR = 1.38; 95%CI = 0.85-2.25, respectively), especially among ever smokers (OR = 1.58; 95%CI = 0.96-2.60), heavy smokers (OR = 2.07; 95%CI = 0.74-5.75), and adenocarcinoma (OR = 1.88; 95%CI = 0.97-3.63). On the other hand, individuals homozygous for the XRCC1 399Gln allele presented no risk of developing lung cancer (OR = 0.87; 95%CI = 0.57-1.31) except for individuals carriers of 399Gln/Gln genotype and without family history of cancer (OR = 0.57; 95%CI = 0.33-0.98) and no association was found between XRCC3 Thr241Met polymorphism and lung cancer risk (OR = 0.92; 95%CI = 0.56-1.50), except for the 241Met/Met genotype and squamous cell carcinoma risk (OR = 0.47; 95%CI = 0.23-1.00).
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 203 210 <span type="species:ncbi:4097">tobacco</span>
In conclusion, we analysed the association between XPC, XPD, XRCC1, and XRCC3 polymorphisms and the individual susceptibility to develop lung cancer in the Spanish population, specifically with a highly tobacco exposed population. We attempt to contribute to the discovery of which biomarkers of DNA repair capacity are useful for screening this high-risk population for primary preventing and early detection of lung cancer.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 445 446 445 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 402 405 <span type="species:ncbi:9606">men</span>
Lung cancer is the most common cancer in the world, in 2002 there were 1.35 million new cases, representing 12.4% of total cancers. It was also the most common cause of death from cancer, with 1.18 million global deaths, representing 17.6% of the total deaths from cancer. Almost half (49.9%) of the cases occur in the developing countries of the world [1]. In Spain, lung cancer is the main cancer in men, accounting for 16,628 deaths in 2004 [2].
###end p 11
###begin p 12
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 249 250 249 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 391 392 391 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 393 394 393 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 840 841 840 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 526 533 <span type="species:ncbi:4097">tobacco</span>
###xml 629 634 <span type="species:ncbi:9606">human</span>
Although cigarette smoking is the major cause of lung cancer, only a small fraction of smokers develop this disease, suggesting that other causes, including genetic susceptibility, might contribute to the variation in individual lung cancer risk [3,4]. This genetic susceptibility may result from inherited polymorphisms in the genes involved in carcinogen metabolism and DNA damage repair [5-7]. DNA repair systems play a critical role protecting the genome from insults caused by carcinogenic agents, such as those found in tobacco smoke [8]. Until now, more than a hundred proteins implicated in DNA repair have been found in human cells. These proteins are implicated in four major DNA repair pathways, including nucleotide excision repair (NER), base excision repair (BER), double-strand break repair (DSBR) and mismatch repair (MMR) [9,10].
###end p 12
###begin p 13
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 195 200 <span type="species:ncbi:9606">human</span>
Polymorphisms affecting the coding sequence of a gene are very common in the population, and many of them result in changes that alter protein function [11]. In this sense, the completion of the human genome sequence has allowed the identification of numerous polymorphisms in DNA repair genes, and many of them have been shown to contribute to genetic instability and error accumulation due to reduced protein activity. The gene encoding the NER protein XPC constitutes an excellent example, because a relationship between polymorphism and altered gene function has been established.
###end p 13
###begin p 14
###xml 72 76 72 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 186 190 186 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 314 316 314 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 528 535 528 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn </italic>
###xml 539 546 539 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">751Gln </italic>
###xml 549 553 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 650 652 650 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 730 741 730 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn/Asn </italic>
###xml 745 756 745 756 <italic xmlns:xlink="http://www.w3.org/1999/xlink">751Gln/Gln </italic>
###xml 850 852 850 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 992 996 992 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 1000 1004 1000 1004 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 1005 1007 1005 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1008 1010 1008 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1131 1133 1131 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1134 1136 1134 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1239 1240 1239 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1241 1243 1241 1243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1035 1041 <span type="species:ncbi:9606">humans</span>
In a previous report, we have shown that individuals homozygous for the XPC PAT polymorphism have an increased risk of developing lung cancer [12]. Nevertheless, PAT polymorphism in the XPC gene has been associated with an increased risk of developing different types of cancer, including smoking-related cancers [13-15] or melanoma [16]. Polymorphisms in other DNA repair NER genes have also been associated with individual susceptibility to develop cancer, including the gene encoding XPD. The presence of the variant alleles 312Asn and 751Gln of XPD have been associated with relatively high risk of lung cancer in Caucasian [17-20] and Asian [21-24] populations and a recent meta-analysis concludes that the variant genotypes 312Asn/Asn and 751Gln/Gln are associated with a statistically significant lung cancer risk in the Caucasian population [25]. Moreover, several studies have carried out combined analysis between lung cancer risk and polymorphisms in different NER genes including XPC and XPD [19,26]. Functional studies in humans have shown that common polymorphisms in NER genes can modify the capacity to repair DNA [27-29], and epidemiologic studies have supported their role in the pathogenesis of smoking-related cancers [7,30].
###end p 14
###begin p 15
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 211 213 211 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 489 491 489 491 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 492 494 492 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 683 685 683 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 122 129 <span type="species:ncbi:4097">tobacco</span>
BER genes play a key role by removing DNA damage from oxidation, deamination, and ring fragmentation [31] and exposure to tobacco smoking induces oxidative damage by generation of reactive oxygen species (ROS) [32]. Therefore, polymorphisms in BER genes may be associated with lung cancer. The association between the XRCC1 Arg399Gln polymorphism, resulting from a guanine to adenine nucleotide change, and lung cancer risk has been evaluated in a number of epidemiological studies [19,20,33-39]. A recent meta-analysis including 7385 cases and 9381 controls showed that 399Gln/Gln genotype was associated with an increased risk of lung cancer among Asians but not among Caucasians [37]. A multicenter study conducted in Europe concluded that this polymorphism was not associated with lung cancer risk [34].
###end p 15
###begin p 16
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 658 660 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 664 666 664 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 667 669 667 669 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 196 203 <span type="species:ncbi:4097">tobacco</span>
Finally, DSBR pathway is the responsible for repairing double-strand breaks. These result from exogenous agents such as ionizing radiation or environmental carcinogens, including those present in tobacco smoke and from endogenously generated ROS. They can also be produced when DNA replication encounter DNA single-strand breaks or other types of lesion [40]. XRCC3, which participates in DNA double-strand break via homologous recombinational repair, presents a non-conservative Thr241Met substitution in exon 7. Until now, there are several conflicting reports on the association between this polymorphism and lung cancer risk in the Caucasian population [19,20,38,41-43].
###end p 16
###begin p 17
###xml 194 202 194 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC, XPD</italic>
###xml 204 209 204 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 211 216 211 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3</italic>
###xml 324 331 <span type="species:ncbi:4097">tobacco</span>
In order to examine if genetic polymorphisms in DNA repair genes implicated in NER, BER and DSBR pathways are associated with lung cancer risk, we have studied five polymorphisms in four genes (XPC, XPD, XRCC1, XRCC3) in 516 cases and 533 controls of a Caucasian population of Northern Spain, historically highly exposed to tobacco.
###end p 17
###begin title 18
Methods
###end title 18
###begin title 19
Study population
###end title 19
###begin p 20
###xml 214 222 <span type="species:ncbi:9606">Patients</span>
###xml 543 551 <span type="species:ncbi:9606">Patients</span>
###xml 668 676 <span type="species:ncbi:9606">patients</span>
###xml 1232 1243 <span type="species:ncbi:9606">participant</span>
The CAPUA study (Cancer de Pulmon en Asturias) is a hospital-based case-control study conducted in the "Unidad de Epidemiologia Molecular del Cancer, Instituto Universitario de Oncologia" of Universidad de Oviedo. Patients were recruited in two main hospitals following an identical protocol from October 2000 to April 2005. Eligible cases were incident cases of histologically confirmed lung cancer between 30 and 85 years of age and residents in the geographical area of each participating hospital for at least six months before diagnosis. Patients with primary cancer other than lung cancer occurring in the last 5 years were excluded. Controls were selected from patients admitted to participating hospitals for diagnoses believed to be unrelated to the exposures of interest, individually matched to the cases on ethnicity, gender and age (+/- 5 years). The main specific pathologies of the final controls selected were: 41.1% inguinal and abdominal hernias (ICD-9: 550-553), 32.5% injuries (ICD-9: 800-848, 860-869, 880-897), 8.8% appendicitis (ICD-9: 540), and 13.3% intestinal obstructions (ICD-9: 560, 569, 574). The study was approved by the ethical committee of the hospitals, and written consent was obtained from each participant.
###end p 20
###begin title 21
Data collection
###end title 21
###begin p 22
###xml 306 313 <span type="species:ncbi:4097">tobacco</span>
###xml 372 379 <span type="species:ncbi:4097">tobacco</span>
###xml 476 487 <span type="species:ncbi:9606">participant</span>
Information on known or potential risk factors for lung cancer was collected personally through computer-assisted questionnaires by trained interviewers during the first hospital admission for diagnosis. Structured questionnaires collected information on sociodemographic characteristics, recent and prior tobacco use, environmental exposure (air pollution, environmental tobacco smoking (ETS)), diet, personal and family history of cancer, and occupational history from each participant. A total of 93.8% eligible cases and 98.5% of eligible controls agreed to participate in the study and were interviewed. Of the 759 cases and 593 controls interviewed, 741 (97.6%) cases and 556 (93.8%) controls provided a blood or buccal cell sample for DNA extraction. Seventeen individuals (five cases and twelve controls) were excluded because of low amounts of DNA. 37 individuals (twenty six cases and eleven controls) with missing information in the questionnaires and 194 cases without matched controls were also excluded from the analyses. Thus, the final study population available for analysis was 516 cases and 533 controls, all of whom were Caucasian.
###end p 22
###begin title 23
###xml 0 7 <span type="species:ncbi:4097">Tobacco</span>
Tobacco exposure information
###end title 23
###begin p 24
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 802 809 <span type="species:ncbi:4097">tobacco</span>
Participants were defined as never smokers if they had not smoked >100 cigarettes in their lifetime and ever smokers otherwise. Ever smokers were further classified as current smokers if they had smoked at least one cigarette per day for 6 months or longer. Individuals who had smoked regularly but who had stopped smoking at least 1 year before the interview were defined as former smokers. ETS exposure was quantified determining the source, intensity, and duration of exposure during childhood and adulthood [44]. Smoking intensity (pack-years, PY) was defined as the number of packs of cigarettes smoked per day multiplied by the number of years smoking. We categorized the subjects as light (</= 16.45 PY), moderate (> 16.45-53 PY), or heavy (> 53 PY) smokers based on the quartiles of cumulative tobacco consumption among the control group.
###end p 24
###begin title 25
Genotype analysis
###end title 25
###begin p 26
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 592 593 592 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 612 616 612 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 650 654 650 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 750 751 750 751 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 803 805 803 805 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 830 834 830 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 855 859 855 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 878 884 878 884 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 898 904 898 904 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 1067 1068 1067 1068 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1089 1095 1089 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 1203 1206 1203 1206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nco</italic>
###xml 1351 1355 1350 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Taq </italic>
###xml 1449 1453 1448 1452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 1765 1766 1758 1759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 418 430 <span type="species:ncbi:9606">participants</span>
Laboratory personnel were blinded to case and control status. Genomic DNA was extracted from peripheral blood samples (96.5% of total) or exfoliated buccal cells (3.5% of total) as previously described [45]. For quality control, genotyping was repeated randomly in at least 5% of the samples, and two of the authors independently reviewed all results. A quality control of 50 blood and mouthwash samples from the same participants ensured the reliability of genotyping results of mouthwash samples. In both quality controls no differences were found. Polymorphisms studied are shown in Table 1. To determine the XPC PAT polymorphism, intron 9 of the XPC gene was amplified by polymerase chain reaction (PCR) using the oligonucleotides shown in Table 2 (primers and conditions were previously described [12]). The polymorphisms in XPD exon 10 (rs1799793), XPD exon 23 (rs13181), XRCC1 (rs25487) and XRCC3 (rs861539) were analysed by PCR combined with restriction fragment length polymorphism (RFLP). Details of PCR primers and cycle conditions used are shown in Table 2. In the case of the XRCC3 gene, the reverse primer was specially designed to introduce the recognition site of the restriction enzyme NcoI by replacing a G with a C (lower case). PCR was performed in a 10 mul mixture containing 20 ng of genomic DNA, 0.25 mM each dNTP, 0.5 units of Taq polymerase (Biotools), and 10 pmol of each primer in 1 x PCR buffer. For the amplification of XPD exon 10, dimethylsulfoxide was added to the reaction at a final concentration of 3%. PCR products were digested overnight with the indicated restriction enzyme at 37degreesC. DNA fragments were resolved on agarose gels and stained with ethidium bromide (restriction enzyme and fragments sizes are shown in Table 1). To verify that the data obtained by RFLP was coincident with the allele sequence, representative fragments were further purified for PCR-directed sequencing to confirm the different polymorphisms (data not shown).
###end p 26
###begin p 27
Details of RFLPs studied and fragments sizes
###end p 27
###begin p 28
* Reference SNP accession numbers are indicated for each polymorphism
###end p 28
###begin p 29
Details of PCR conditions for polymorphism analysis
###end p 29
###begin title 30
Statistical analysis
###end title 30
###begin p 31
###xml 112 114 110 112 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 367 368 363 364 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 489 491 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 858 861 854 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 863 866 859 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 868 874 864 870 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 877 882 873 878 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3</italic>
Tests for Hardy-Weinberg equilibrium among controls were conducted using observed genotype frequencies and a chi2 test with one degree of freedom. Univariate analysis was first performed to compare the distribution of age and gender and the frequencies of alleles and genotypes. The differences in the distribution between cases and controls were tested using the chi2, Fisher exact, and Mann-Whitney U-test, where appropriate. The crude odd ratios (ORs) were calculated by Wolf's method [46]. Multivariate unconditional logistic regression analysis with adjustment for age, gender, and pack-years was performed to calculate adjusted ORs and 95% confidence intervals (CIs). Gene-gene and gene-environment interactions were estimated by the logistic regression model, which included an interaction term as well as variables for exposure (smoking), genotypes (XPC, XPD, XRCC1 or XRCC3) and potential confounders (age and gender). All statistical analyses were performed with STATA version 8 software.
###end p 31
###begin p 32
The sample size of our study for an allele frequency between 29-32% is enough to detect ORs greater than 1.38 with more than 90% power assuming a log-additive model. For allele frequencies of 40%, the power to detect an OR of 1.28 is 79%. For allele frequencies between 30-40% as observed for polymorphisms analysed in this study, the power to detect an OR greater than 2.00 for the interaction gen-gen is more than 90%. Allele frequencies of controls were calculated using following formula (example genotypes AA, AB, BB): Allele B frequency = [number genotypes AB + 2 x (number genotypes BB)]/[2 x (number genotypes AA + number genotypes AB + number genotypes BB)].
###end p 32
###begin title 33
Results
###end title 33
###begin title 34
Subject characteristics
###end title 34
###begin p 35
###xml 282 283 282 283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 575 577 575 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 616 618 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vs</italic>
###xml 698 700 698 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 803 810 <span type="species:ncbi:4097">tobacco</span>
###xml 856 863 <span type="species:ncbi:4097">tobacco</span>
The analysis included 516 lung cancer cases and 533 controls from the Caucasian population of Asturias, Northern Spain. The distributions of age, gender, smoking history, family history of cancer, and histological type for the cases among the study subjects are summarized in Table 3. There were no statistically significant differences among cases and controls in terms of mean age and gender distributions, suggesting that the frequency matching was adequate. There is only a never smoker case of lung cancer without ETS exposure and there were more current smokers (53.2% vs. 39.9%) and more heavy smokers (62.85 vs. 40.41 number of pack-years, PY) in the study cases than in the control group (P < 0.001). There is a statistically significant difference between cases and controls regarding type of tobacco smoked, 75.3% of cases were smokers of black tobacco (black smokers), exclusively. Histologically, squamous cell carcinoma (40.3%) and adenocarcinoma (29.5%) are the main types of lung cancer presented.
###end p 35
###begin p 36
###xml 49 57 <span type="species:ncbi:9606">patients</span>
Characteristics of lung cancer cases and control patients in a Spanish population
###end p 36
###begin p 37
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 15 17 13 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
a Two-sided chi2 test and Mann-Whitney where appropriate
###end p 37
###begin p 38
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
b Pack-years for ever smokers
###end p 38
###begin p 39
###xml 106 110 106 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 115 119 115 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 145 151 145 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 166 172 166 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
We have determined the frequency of 5 polymorphisms in 4 different genes implicated in DNA damage repair (XPC PAT, XPD Asp312Asn, XPD Lys751Gln, XRCC1 Arg399Gln, and XRCC3 Thr241Met) in lung cancer patients and matched controls in order to evaluate their association with the risk of lung cancer. The genotype distribution for all the SNPs studied was consistent with Hardy-Weinberg equilibrium. In the multivariate logistic regression model, there was no evidence for any interaction between variant genotypes and smoking (data not shown).
###end p 39
###begin title 40
###xml 16 24 16 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT </italic>
Analysis of the XPC PAT genotype
###end title 40
###begin p 41
###xml 21 30 21 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT+ </italic>
###xml 106 113 106 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAT+/+ </italic>
###xml 214 216 214 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 364 369 364 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAT+ </italic>
###xml 486 488 486 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
The frequency of the XPC PAT+ allele was 0.431 in study cases and 0.401 in controls. The frequency of the PAT+/+ genotype was higher in the study cases (19.6%) than in controls (15.8%), although not significantly (P = 0.260) (Table 4). When we analysed the association between XPC genotypes and lung cancer risk, we found that those individuals homozygous for the PAT+ allele presented a not statistically significant higher risk of lung cancer (adjusted OR = 1.28; 95% CI = 0.85-1.92, P = 0.229).
###end p 41
###begin p 42
Analysis of polymorphisms and lung cancer risk estimates
###end p 42
###begin p 43
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 41 48 <span type="species:ncbi:4097">tobacco</span>
a Adjusted by age, gender and cumulative tobacco consumption (in pack-years: </= 16.45, > 16.45-53 and > 53)
###end p 43
###begin p 44
###xml 55 66 55 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT+/+ </italic>
###xml 202 204 202 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 278 280 278 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 356 363 356 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAT+/+ </italic>
###xml 518 520 518 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 589 591 589 591 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 621 622 621 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Stratified analysis for smoking status showed that the XPC PAT+/+ genotype was associated with a not statistically significant increased risk among ever smokers (adjusted OR = 1.40; 95% CI = 0.94-2.08, P = 0.100) and heavy black smokers (adjusted OR = 1.55; 95% CI = 0.62-3.87, P = 0.350) and stratification for histological type revealed that the variant PAT+/+ genotype was associated with a not statistically significant increased risk of developing squamous cell carcinoma (adjusted OR = 1.44; 95% CI = 0.85-2.44, P = 0.175) and adenocarcinoma (adjusted OR = 1.72; 95% CI = 0.97-3.04, P = 0.064) [see Additional file 1].
###end p 44
###begin title 45
###xml 61 65 61 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
Analysis of the Asp312Asn and Lys751Gln polymorphisms in the XPD gene
###end title 45
###begin p 46
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 415 422 415 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn </italic>
###xml 426 433 426 433 <italic xmlns:xlink="http://www.w3.org/1999/xlink">751Gln </italic>
###xml 619 620 619 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 728 732 728 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 747 758 747 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn/Asn </italic>
###xml 762 772 762 772 <italic xmlns:xlink="http://www.w3.org/1999/xlink">751Gln/Gln</italic>
###xml 895 897 895 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 946 948 946 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Analysis of the two most common polymorphisms in the XPD gene, Asp312Asn in exon 10 and Lys751Gln in exon 23, revealed that the two polymorphisms were in linkage disequilibrium with 20% of discrepancies, which is in agreement with previous reports [17,18,47,48]. Due to this linkage between both polymorphisms, the OR observed for each allele, either global or stratified, were very similar. The frequencies of the 312Asn and 751Gln alleles were 0.321 and 0.340 among study cases and 0.296 and 0.319 among controls, respectively. Genotype distribution and calculated ORs were very similar for both polymorphisms (Table 4), although a higher risk was observed for the Asp312Asn polymorphism. Those individuals homozygous for the XPD polymorphisms (312Asn/Asn and 751Gln/Gln) presented a not statistically significant higher risk of developing lung cancer (adjusted OR = 1.52; 95% CI = 0.91-2.51, P = 0.106; adjusted OR = 1.38; 95% CI = 0.85-2.25, P = 0.193, respectively).
###end p 46
###begin p 47
###xml 36 47 36 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn/Asn </italic>
###xml 183 185 183 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 369 371 369 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 401 402 401 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
Stratified analysis showed that the 312Asn/Asn genotype was associated with a not statistically significant increased risk among ever smokers (adjusted OR = 1.58; 95% CI = 0.96-2.60, P = 0.074) and heavy smokers (adjusted OR = 2.07; 95% CI = 0.74-5.75, P = 0.165), as well as with an increased risk of developing adenocarcinoma (adjusted OR = 1.88; 95% CI = 0.97-3.63, P = 0.061) [see Additional file 2].
###end p 47
###begin title 48
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
Analysis of the Arg399Gln polymorphism in the XRCC1 gene
###end title 48
###begin p 49
###xml 21 34 21 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 399Gln </italic>
###xml 110 118 110 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gln/Gln </italic>
###xml 239 241 239 241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 282 289 282 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln </italic>
###xml 381 383 381 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 518 529 518 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln/Gln </italic>
###xml 616 618 616 618 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 835 837 835 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 928 930 928 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 960 961 960 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
The frequency of the XRCC1 399Gln allele was 0.358 in study cases and 0.373 in controls. The frequency of the Gln/Gln genotype was lower in the study cases (14.5%) than in controls (15.4%), although this was not statistically significant (P = 0.744). Individuals homozygous for the 399Gln allele presented no risk of developing lung cancer (adjusted OR = 0.87; 95% CI = 0.57-1.31, P = 0.500) (Table 4). Stratified analysis for selected variables confirmed the absence of association except for individuals carriers of 399Gln/Gln genotype and without family history of cancer (adjusted OR = 0.57; 95% CI = 0.33-0.98, P = 0.042), which showed a statistically significant protective effect. This genotype was also associated with a not statistically significant increased risk among light smokers (adjusted OR = 1.62; 95% CI = 0.47-5.56, P = 0.444), but decreased risk for moderate smokers (adjusted OR = 0.67; 95% CI = 0.36-1.24, P = 0.203) [see Additional file 3].
###end p 49
###begin title 50
###xml 46 52 46 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
Analysis of the Thr241Met polymorphism in the XRCC3 gene
###end title 50
###begin p 51
###xml 21 34 21 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 241Met </italic>
###xml 110 121 110 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">241Met/Met </italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 331 333 331 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 448 459 448 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">241Met/Met </italic>
###xml 542 544 542 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 602 603 602 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
The frequency of the XRCC3 241Met allele was 0.354 in study cases and 0.364 in controls. The frequency of the 241Met/Met genotype in XRCC3 was similar in the study cases (12.4%) and in controls (13.8%), and no association was found between XRCC3 Thr241Met polymorphism and lung cancer risk (adjusted OR = 0.92; 95% CI = 0.56-1.50, P = 0.898) (Table 4). Stratified analysis for selected variables confirmed the absence of association except for the 241Met/Met genotype and squamous cell carcinoma risk (adjusted OR = 0.47; 95% CI = 0.23-1.00, P = 0.049) showing a protective effect [see Additional file 4].
###end p 51
###begin title 52
Combined analysis of polymorphisms in DNA repair genes and lung cancer
###end title 52
###begin p 53
###xml 204 208 204 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 213 217 213 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 228 232 228 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 243 249 243 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 263 269 263 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 321 324 321 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 325 333 325 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD, XPC</italic>
###xml 334 340 334 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 348 354 348 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 375 376 375 376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 415 443 415 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT(+/+)/XPD 751Lys/Gln </italic>
###xml 446 474 446 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT(+/+)/XPD 751Gln/Gln </italic>
###xml 511 513 511 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 554 556 554 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 693 720 693 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT(-/-)/XPD 751Lys/Lys</italic>
###xml 778 784 778 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 926 930 926 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 933 936 933 936 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 1015 1045 1015 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT(+/+)/XRCC3 241Met/Met </italic>
###xml 1048 1080 1048 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD 751Gln/Gln/XRCC3 241Met/Met </italic>
###xml 1177 1179 1177 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1215 1217 1215 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Finally, in order to test whether individual polymorphisms in DNA repair genes might interact and modify the risk of developing lung cancer, ORs were estimated for each pair of the studied polymorphisms (XPC PAT, XPD Asp312Asn, XPD Lys751Gln, XRCC1 Arg399Gln and XRCC3 Thr241Met). Our results show an interaction between XPC/XPD, XPC/XRCC3 and XPD/XRCC3 polymorphisms (Table 5). In fact, individuals with genotypes XPC PAT(+/+)/XPD 751Lys/Gln or XPC PAT(+/+)/XPD 751Gln/Gln showed a 1.63-fold (CI = 0.89-2.98), P = 0.111, and 2.25-fold (CI = 0.83-6.13), P = 0.202, higher risk of lung cancer, respectively, when compared with homozygous carriers of the wild type allele of both polymorphisms (XPC PAT(-/-)/XPD 751Lys/Lys). Furthermore, despite the fact that the polymorphism in XRCC3 didn't alter the overall risk of developing lung cancer when studied independently, when this polymorphism was combined with those studied in XPC or XPD, we observed an interaction between these polymorphisms. Individuals with the XPC PAT(+/+)/XRCC3 241Met/Met or XPD 751Gln/Gln/XRCC3 241Met/Met genotypes showed a not significant higher risk of developing lung cancer 3.06 (CI = 0.91-10.30) (P = 0.071) and 2.66 (CI = 0.74-9.62) (P = 0.135) respectively.
###end p 53
###begin p 54
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
Combined analysis for XPC, XPD and XRCC3 polymorphisms and lung cancer risk estimates
###end p 54
###begin p 55
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a </sup>
###xml 41 48 <span type="species:ncbi:4097">tobacco</span>
a Adjusted by age, gender and cumulative tobacco consumption (in pack-years: </= 16.45, > 16.45-53 and > 53)
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 367 371 367 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 375 378 375 378 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 460 468 460 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT+</italic>
###xml 470 481 470 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD 312Asn </italic>
###xml 484 495 484 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD 751Gln </italic>
###xml 802 808 802 808 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 812 817 812 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3</italic>
###xml 882 886 882 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 890 894 890 894 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 993 996 993 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 997 1003 997 1003 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 1007 1010 1007 1010 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 1011 1017 1011 1017 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 654 662 <span type="species:ncbi:9606">patients</span>
In this study, we have examined whether polymorphisms in four DNA repair genes involved in the nucleotide excision (NER), base excision (BER), and double-strand break (DSBR) DNA repair pathways are implicated in the development of lung cancer in a Caucasian population from Asturias, Northern Spain. Our results support that polymorphisms in two different NER genes (XPC and XPD) increased the risk of developing lung cancer, so individuals homozygous for the XPC PAT+, XPD 312Asn or XPD 751Gln alleles have a higher risk of developing lung cancer (ORs 1.28, 1.52 and 1.38, respectively). This association was particularly important for ever smokers and patients with adenocarcinomas. On the other hand, no association was found between two genes that participate in the BER and DSBR repair processes (XRCC1 and XRCC3) and the risk of lung cancer. Additionally, interaction between XPC and XPD polymorphisms showed an increased risk of lung cancer (OR = 2.25). Similarly, interactions between XPC/XRCC3 and XPD/XRCC3 were observed, suggesting that coordination between both repair systems might contribute to the individual susceptibility to develop cancer.
###end p 57
###begin p 58
###xml 1122 1127 1122 1127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 1130 1132 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 979 987 <span type="species:ncbi:9606">patients</span>
Our study has several strengths, including high participation of eligible cases (rate 93.8%), quite large sample size from a homogeneous population of same ancestors (516 cases and 533 controls) and the fact that all our control subjects were under Hardy-Weinberg equilibrium. Nevertheless all our cases were pathology confirmed and finally we applied a severe quality control from genotyping. The main limitations of our study were hospital-based subjects, recall bias due to the fact that information on smoking exposure was obtained retrospectively, and especially possible false positive associations, due to multiple comparisons made, we cannot exclude the possibility that some of these associations may represent chance finding, because the power to detect interactions was limited. On the other hand, we have to bear in mind that 26% of controls were ETS exposed which could lead to underestimate our results. To limit selection bias, we carefully selected controls from patients admitted for various diagnoses that were thought to be unrelated to exposures of interest. Nevertheless, a recent paper from Campbell et al. [49] reported that European populations may display various levels of genetic substructure which may lead to false positive associations due to population stratification. In our study, we controlled for this possibility by matching individuals on the basis of European ancestry.
###end p 58
###begin p 59
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 133 137 133 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 148 171 148 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PAT+/939Gln/intron 11 A</italic>
###xml 326 330 326 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A/A </italic>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
We have previously shown that the PAT+ allele is in complete linkage disequilibrium with the intron 11 A-allele [12], reflecting the XPC haplotype (PAT+/939Gln/intron 11 A) with a reduced ability to repair DNA lesions and an increased risk of developing lung cancer. Previous functional analysis has shown that cells with the A/A genotype at the splice acceptor site in intron 11 have a higher frequency of deletion of exon 12 [50], suggesting that this mechanism might contribute to the reduced ability of individuals with this genotype to repair DNA lesions. Nevertheless, the effect of the Lys939Gln polymorphism on the biochemical activity of XPC is still under investigation.
###end p 59
###begin p 60
###xml 53 57 53 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 164 166 164 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 590 597 590 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">939Gln </italic>
###xml 605 607 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 608 610 608 610 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
Several reports have shown that polymorphisms in the XPC gene increase the risk of different tumor types, including smoking-related cancers and cutaneous melanoma [13-16,51,52]. For lung cancer, the number of studies is still very limited. A recent study carried out in an Asiatic population of 432 cases and 432 controls was unable to find any association between the XPC PAT polymorphism and the risk of developing lung cancer [53]. However, other reports studying the exon 15 polymorphism in Danish and Chinese populations have found an increased risk for developing lung cancer for the 939Gln allele [26,54], similar to our results.
###end p 60
###begin p 61
###xml 4 11 4 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">312Asn </italic>
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">751Gln </italic>
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 168 170 168 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 307 309 307 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 466 468 466 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
The 312Asn and 751Gln alleles in the XPD gene have been associated with a reduced capacity to repair BPDE and UV-induced damage in host cell reactivation assays [48,55,56] and with a higher DNA adduct, chromosomal aberrations, and single-strand breaks level which is interpreted as lower repair efficiency [27,28,57-59]. Our results confirm an association between these polymorphisms and the risk of developing lung cancer, and extend previous findings [17-22,24,25,60].
###end p 61
###begin p 62
###xml 218 220 218 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 735 737 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 909 911 909 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 912 914 912 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 915 917 915 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 78 85 <span type="species:ncbi:4097">Tobacco</span>
Our results for the stratified analysis are supported by biological evidence. Tobacco smoke increases the risk of lung cancer and increases the risk for all histological types of this cancer, including adenocarcinoma [61]. Our results showed higher risk for adenocarcinoma, although the reason for the observed histology-dependent difference in the genetic effect conferred by these polymorphisms is unknown, being perhaps a bit too hypothetical, it may be attributable to differences in the carcinogenesis pathways among the histological types of lung cancer. Various lines of evidence have suggested that the histological type of lung cancer may be determined by the particular initiating agent to which an individual is exposed [62,63], which need to be verified in further studies. Therefore, genetic factors involved in susceptibility could be different between the histological subtypes of lung cancer [21,24,53].
###end p 62
###begin p 63
###xml 129 135 129 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 139 144 139 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3</italic>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 622 624 622 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 711 722 711 722 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln/Gln </italic>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 933 940 933 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln </italic>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 1079 1086 1079 1086 <italic xmlns:xlink="http://www.w3.org/1999/xlink">399Gln </italic>
Contrary to the results observed with polymorphisms in genes that participate in the NER mechanism, the polymorphisms studied in XRCC1 and XRCC3, implicated in other DNA repair processes such as BER and DSBR, were not associated to the global individual susceptibility to develop lung cancer. Previous studies of XRCC1 Arg399Gln polymorphism have shown contradictory results, several reports have found association with different types of cancer, including colorectal, breast, lung or melanoma [64-70], while other reports have failed to find association with some of these pathologies, or even found a protective effect [71-73]. Our data showed no association between XRCC1 Arg399Gln and lung cancer risk, but 399Gln/Gln genotype showed a not significant increased risk for light smokers, suggesting any kind of effect modification as Hung et al. concluded for all smoking related cancers [74]. These results fit in studies showing 399Gln allele may be associated with higher mutagen sensitivity and higher levels of DNA adducts [75] who reported that never smokers carriers of 399Gln had higher DNA adduct levels than current smokers.
###end p 63
###begin p 64
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC</italic>
###xml 10 17 10 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">241Met </italic>
###xml 87 89 87 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 161 163 161 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 230 236 230 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 315 317 315 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 446 448 446 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 625 627 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 745 747 745 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
The XRCC3 241Met allele has previously been associated with less efficient DNA repair [75], as well as an increased number of centrosomes and binucleated cells [76]. However, it has also been shown that the common and the variant XRCC3 alleles are functionally equivalent in the double-strand break repair pathway [77], which may explain the lack of association between XRCC3 Thr241Met polymorphism and lung cancer risk shown in several studies [41,42,47]. In the Caucasian population, there are inconclusive and conflicting results: several studies have found an increased risk for non small cell carcinoma and lung cancer [19,43], while other studies have shown a protective effect, once more for non small cell carcinoma and ever smokers [20,38]. Our study showed a statistically significant protective effect for squamous cell carcinoma, but it is difficult to assess the effect of this single common sequence variant because it might not be detectable in population association studies being necessary larger samples.
###end p 64
###begin p 65
###xml 493 494 493 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 495 497 495 497 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 432 439 <span type="species:ncbi:4097">tobacco</span>
We have found that polymorphisms in NER genes increase the risk of developing lung cancer, while no association was found between polymorphisms in BER and DSBR genes and lung cancer risk. These results might reflect differences in the etiology of different carcinomas, or a more important role of the NER repair pathways in the development of lung cancer. In this regard, numerous studies have shown that most DNA lesions caused by tobacco-smoke carcinogens are repaired by the NER mechanism [8,78,79], suggesting that this particular cancer could be more susceptible to polymorphisms affecting genes implicated in the NER pathway.
###end p 65
###begin p 66
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 321 332 321 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT+/+ </italic>
###xml 335 349 335 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD 751Gln/Gln</italic>
###xml 671 673 671 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 707 711 707 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 715 719 715 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
Although the relative risks for individuals carrying the polymorphisms in XPC and XPD genes are modest (ORs < 1.52), these polymorphisms could account for a large proportion of lung cancers, as they are very common in the population. In fact, between 9% and 16% of individuals are homozygous for the high-risk genotypes (XPC PAT+/+ or XPD 751Gln/Gln). In this regard, we observed a borderline combined effect between these polymorphisms and the risk of lung cancer, as individuals homozygous for both risk genotypes showed a further increase in the risk of developing lung cancer than that observed for the individual polymorphisms (adjusted OR = 2.25; 95% CI 0.83-6.13, P = 0.202). This combined effect of XPC and XPD polymorphisms could support the hypothesis for this population that changes in genes implicated in the NER repair pathway contribute to the susceptibility of developing lung cancer, and the combination of genotypes with a reduced ability to repair DNA lesions could result in a higher risk of developing this disease.
###end p 66
###begin p 67
###xml 28 45 28 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 241Met/Met </italic>
###xml 63 74 63 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC PAT+/+ </italic>
###xml 81 96 81 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD 751Gln/Gln </italic>
###xml 145 146 145 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
Similarly, when we combined XRCC3 241Met/Met genotype with the XPC PAT+/+ or the XPD 751Gln/Gln genotypes, an increased risk was observed (Table 5). These results could suggest that the DSBR mechanism might also play a role in the development of lung cancer when combined with certain NER genes genotypes. Indeed, smoking induces a great variety of DNA damage, which must be repaired by more than one repair pathway, being NER the main pathway and DSBR the second, thus the combined occurrence of genetic variants in these two repair pathways might contribute to a greater risk of lung cancer. The approach of using combined analysis of polymorphisms may represent an alternative way of analyzing the overall effect of the different genetic variants as well as the potential joint effect of these genes.
###end p 67
###begin title 68
Conclusion
###end title 68
###begin p 69
###xml 51 54 51 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC</italic>
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD</italic>
###xml 61 66 61 66 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1</italic>
###xml 72 78 72 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 203 210 <span type="species:ncbi:4097">tobacco</span>
In conclusion, we analysed the association between XPC, XPD, XRCC1, and XRCC3 polymorphisms and the individual susceptibility to develop lung cancer in the Spanish population, specifically with a highly tobacco exposed population. We attempt to contribute to the discovery of which biomarkers of DNA repair capacity are useful for screening high-risk populations for primary preventing and early detection of lung cancer. To further evaluate gene-gene and gene-environment interactions between this polymorphisms and lung cancer risk in our population, a single larger sample with thousands of subjects and tissue-specific biochemical and biological characterizations are required. Finally, higher sample size will be also required to confirm small associations and to evaluate complex interrelationships between genetic variants and smoking type and status.
###end p 69
###begin title 70
Competing interests
###end title 70
###begin p 71
The author(s) declare that they have no competing interests.
###end p 71
###begin title 72
Authors' contributions
###end title 72
###begin p 73
###xml 260 267 <span type="species:ncbi:9606">patient</span>
MFLC carried out the molecular genetic studies and draft the manuscript. PGA participated in the molecular genetic studies. LGC participated in the design of the study, performed the statistical analysis, and revised the manuscript. TP and MGM participated in patient enrollment. XSP participated in the molecular genetic studies. AT conceived of the study, participated in its design and coordination, and revised the manuscript. All authors read and approved the final manuscript.
###end p 73
###begin title 74
Pre-publication history
###end title 74
###begin p 75
The pre-publication history for this paper can be accessed here:
###end p 75
###begin p 76

###end p 76
###begin title 77
Supplementary Material
###end title 77
###begin title 78
Additional file 1
###end title 78
###begin p 79
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
###xml 130 134 130 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPC </italic>
Table 6 - Analysis of XPC PAT stratified by selected variables. This table shows the stratified analysis by selected variables of XPC PAT polymorphism
###end p 79
###begin p 80
Click here for file
###end p 80
###begin title 81
Additional file 2
###end title 81
###begin p 82
###xml 22 26 22 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
###xml 134 138 134 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XPD </italic>
Table 7 - Analysis of XPD exon 10 stratified by selected variables. This table shows the stratified analysis by selected variables of XPD exon 10 (Asp312Asn) polymorphism
###end p 82
###begin p 83
Click here for file
###end p 83
###begin title 84
Additional file 3
###end title 84
###begin p 85
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC1 </italic>
Table 8 - Analysis of XRCC1 Arg399Gln stratified by selected variables. This table shows the stratified analysis by selected variables of XRCC1 Arg399Gln polymorphism
###end p 85
###begin p 86
Click here for file
###end p 86
###begin title 87
Additional file 4
###end title 87
###begin p 88
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
###xml 138 144 138 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">XRCC3 </italic>
Table 9 - Analysis of XRCC3 Thr241Met stratified by selected variables. This table shows the stratified analysis by selected variables of XRCC3 Thr241Met polymorphism
###end p 88
###begin p 89
Click here for file
###end p 89
###begin title 90
Acknowledgements
###end title 90
###begin p 91
###xml 22 30 <span type="species:ncbi:9606">patients</span>
We are in debt to the patients who participated in the study. We also thank the study monitors Cristina Arias and Avelino Menendez (Unidad de Epidemiologia Molecular - IUOPA) for collecting information. We thank Dr. Kevin Dalton for proofreading the text.
###end p 91
###begin article-title 92
Global cancer statistics, 2002
###end article-title 92
###begin article-title 93
Centro Nacional de Estadistica. Defunciones segun la causa de muerte en Espana
###end article-title 93
###begin article-title 94
Leisure-time physical activity and lung cancer: a meta-analysis
###end article-title 94
###begin article-title 95
Lung cancer risk in iron and steel foundry workers: a nested case control study in Asturias, Spain
###end article-title 95
###begin article-title 96
Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promises and perils of individual and population risk estimation?
###end article-title 96
###begin article-title 97
Cancer risk and low-penetrance susceptibility genes in gene-environment interactions
###end article-title 97
###begin article-title 98
Polymorphisms in DNA repair genes and associations with cancer risk
###end article-title 98
###begin article-title 99
###xml 37 42 <span type="species:ncbi:4932">yeast</span>
Nucleotide excision repair. II: From yeast to mammals
###end article-title 99
###begin article-title 100
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human DNA repair systems: an overview
###end article-title 100
###begin article-title 101
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human DNA repair genes
###end article-title 101
###begin article-title 102
###xml 23 28 <span type="species:ncbi:9606">human</span>
A haplotype map of the human genome
###end article-title 102
###begin article-title 103
Poly (AT) polymorphism in intron 11 of the XPC DNA repair gene enhances the risk of lung cancer
###end article-title 103
###begin article-title 104
An intronic poly (AT) polymorphism of the DNA repair gene XPC and risk of squamous cell carcinoma of the head and neck: a case-control study
###end article-title 104
###begin article-title 105
Polymorphisms in DNA repair genes in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma
###end article-title 105
###begin article-title 106
Polymorphism in DNA repair genes and oral squamous cell carcinoma in Thailand
###end article-title 106
###begin article-title 107
Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study
###end article-title 107
###begin article-title 108
Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer
###end article-title 108
###begin article-title 109
Two regions in chromosome 19q13.2-3 are associated with risk of lung cancer
###end article-title 109
###begin article-title 110
Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer
###end article-title 110
###begin article-title 111
Polymorphisms of DNA repair genes and risk of non-small cell lung cancer
###end article-title 111
###begin article-title 112
Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population
###end article-title 112
###begin article-title 113
Sequence variations in the DNA repair gene XPD and risk of lung cancer in a Chinese population
###end article-title 113
###begin article-title 114
Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population
###end article-title 114
###begin article-title 115
Polymorphism of the DNA repair gene ERCC2 Lys751Gln and risk of lung cancer in a northeastern Chinese population
###end article-title 115
###begin article-title 116
DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis
###end article-title 116
###begin article-title 117
Combinations of polymorphisms in XPD, XPC and XPA in relation to risk of lung cancer
###end article-title 117
###begin article-title 118
Use of biomarkers to characterize functions of polymorphic DNA repair genotypes
###end article-title 118
###begin article-title 119
Genetic polymorphisms in DNA repair genes and possible links with DNA repair rates, chromosomal aberrations and single-strand breaks in DNA
###end article-title 119
###begin article-title 120
Reduced nucleotide excision repair and GSTM1-null genotypes influence anti-B[a]PDE-DNA adduct levels in mononuclear white blood cells of highly PAH-exposed coke oven workers
###end article-title 120
###begin article-title 121
###xml 61 68 <span type="species:ncbi:4097">tobacco</span>
Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies
###end article-title 121
###begin article-title 122
###xml 48 53 <span type="species:ncbi:9606">human</span>
Commentary: DNA base excision repair defects in human pathologies
###end article-title 122
###begin article-title 123
Repair mechanisms for oxidative DNA damage
###end article-title 123
###begin article-title 124
No association between base excision repair gene polymorphisms and risk of lung cancer
###end article-title 124
###begin article-title 125
Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study
###end article-title 125
###begin article-title 126
###xml 55 62 <span type="species:ncbi:4097">tobacco</span>
XRCC1 polymorphism and lung cancer risk in relation to tobacco smoking
###end article-title 126
###begin article-title 127
Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer
###end article-title 127
###begin article-title 128
Association of genetic polymorphisms in the base excision repair pathway with lung cancer risk: a meta-analysis
###end article-title 128
###begin article-title 129
Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers
###end article-title 129
###begin article-title 130
The DNA repair gene XRCC1 and genetic susceptibility of lung cancer in a northeastern Chinese population
###end article-title 130
###begin article-title 131
DNA double-strand breaks: signaling, repair and the cancer connection
###end article-title 131
###begin article-title 132
No association between the XPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk
###end article-title 132
###begin article-title 133
Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland
###end article-title 133
###begin article-title 134
XRCC3 polymorphisms and risk of lung cancer
###end article-title 134
###begin article-title 135
###xml 46 51 <span type="species:ncbi:9606">women</span>
Passive smoking and lung cancer in nonsmoking women
###end article-title 135
###begin article-title 136
###xml 55 60 <span type="species:ncbi:9606">human</span>
A simple salting out procedure for extracting DNA from human nucleated cells
###end article-title 136
###begin article-title 137
Genetic polymorphisms in DNA repair genes and risk of lung cancer
###end article-title 137
###begin article-title 138
###xml 86 94 <span type="species:ncbi:9606">patients</span>
Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients
###end article-title 138
###begin article-title 139
Demonstrating stratification in a European American population
###end article-title 139
###begin article-title 140
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human XPC DNA repair gene: arrangement, splice site information content and influence of a single nucleotide polymorphism in a splice acceptor site on alternative splicing and function
###end article-title 140
###begin article-title 141
Polymorphisms in DNA repair and metabolic genes in bladder cancer
###end article-title 141
###begin article-title 142
Genetic variation in the nucleotide excision repair pathway and bladder cancer risk
###end article-title 142
###begin article-title 143
XPC polymorphisms and lung cancer risk
###end article-title 143
###begin article-title 144
Polymorphisms in the DNA nucleotide excision repair genes and lung cancer risk in Xuan Wei, China
###end article-title 144
###begin article-title 145
Modulation of repair of ultraviolet damage in the host-cell reactivation assay by polymorphic XPC and XPD/ERCC2 genotypes
###end article-title 145
###begin article-title 146
###xml 196 201 <span type="species:ncbi:9606">human</span>
Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes
###end article-title 146
###begin article-title 147
DNA adduct levels and DNA repair polymorphisms in traffic-exposed workers and a general population sample
###end article-title 147
###begin article-title 148
The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk
###end article-title 148
###begin article-title 149
Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer
###end article-title 149
###begin article-title 150
DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population
###end article-title 150
###begin article-title 151
###xml 0 7 <span type="species:ncbi:4097">Tobacco</span>
Tobacco smoke and involuntary smoking
###end article-title 151
###begin article-title 152
###xml 24 27 <span type="species:ncbi:10116">rat</span>
Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons
###end article-title 152
###begin article-title 153
Cigarette smoking and adenocarcinoma of the lung: the relevance of nicotine-derived nitrosamines
###end article-title 153
###begin article-title 154
Inheritance of the 194Trp and the 399Gln variant alleles of the DNA repair gene XRCC1 are associated with increased risk of early-onset colorectal carcinoma in Egypt
###end article-title 154
###begin article-title 155
Polymorphisms in the DNA repair gene XRCC1 and breast cancer
###end article-title 155
###begin article-title 156
Variants in DNA double-strand break repair genes and breast cancer susceptibility
###end article-title 156
###begin article-title 157
Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to breast cancer
###end article-title 157
###begin article-title 158
The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung
###end article-title 158
###begin article-title 159
Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer
###end article-title 159
###begin article-title 160
A variant within the DNA repair gene XRCC3 is associated with the development of melanoma skin cancer
###end article-title 160
###begin article-title 161
DNA repair gene XRCC1 polymorphisms, smoking, and bladder cancer risk
###end article-title 161
###begin article-title 162
XRCC1 polymorphisms and head and neck cancer
###end article-title 162
###begin article-title 163
Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis
###end article-title 163
###begin article-title 164
Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review
###end article-title 164
###begin article-title 165
XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects
###end article-title 165
###begin article-title 166
Mitotic defects in XRCC3 variants T241M and D213N and their relation to cancer susceptibility
###end article-title 166
###begin article-title 167
Variant XRCC3 implicated in cancer is functional in homology-directed repair of double-strand breaks
###end article-title 167
###begin article-title 168
DNA excision repair
###end article-title 168
###begin article-title 169
The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway
###end article-title 169

